Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

OBN Awards

Now in its 17th year, the OBN Awards are a prestigious and highly sought-after recognition within the life sciences sector. Designed to celebrate innovation and [...]

Go to Top